In the present study, we examined the effects of 5-aza-CdR treatment on the DAPK expression and SN38-sensitivity in these SN38-resistant subclones to investigate the potential therapeutic applications of regulating the DAPK expression and SN38-sensitivity of SN38-resistant cancers. Here, DAPK1 is linked to cancer.